51.07 0.00 (0.00%)
After hours: 4:42PM EST
|Bid||48.50 x 800|
|Ask||52.00 x 1800|
|Day's Range||49.25 - 52.13|
|52 Week Range||27.04 - 52.13|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.75|
REDWOOD CITY, Calif., Feb. 14, 2019 -- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company focused on helping conquer cancer globally through use of its.
The company filed in late September for a $75 million initial public offering but has yet to release any more information, even as a key partnership hits major milestones.
Every investor in Guardant Health, Inc. (NASDAQ:GH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
The LUNAR assay, a new blood-based assay intended to detect early-stage cancer and recurrence of disease, is now available from Guardant Health, Inc. (GH), for research use by biopharmaceutical and academic researchers. The assay, was developed under the company’s LUNAR program for early-stage detection and recurrence monitoring. It is based on biological insights from more than 80,000 cancer patients tested with Guardant360, the industry leading comprehensive liquid biopsy test, as well as learnings from whole-genome sequencing liquid biopsy data.
With hotel stays during next month's J.P. Morgan Healthcare Conference and other nearby events reaching five figures, some wonder if small biotechs are being priced out of San Francisco's big week of meetings with companies and investors.
REDWOOD CITY, Calif., Dec. 20, 2018 -- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company focused on helping conquer cancer globally through use of its.
FDA grants breakthrough device designation to GuardantOMNI test usedfor plasma-based tumor mutational burden analysis in AstraZeneca trial Agreement covers immunotherapy and.
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
Guardant Health Inc. reported earnings late Monday that missed Wall Street profit expectations but beat on sales. It was the company's first earnings since its initial public offering earlier this year. Guardant reported third-quarter net losses of $24.5 million, or $1.94 a share, compared with losses of $33.3 million, or $2.76 a share, in the year-ago period. Revenue rose to $21.7 million from $11.1 million in the year-ago period. The five analysts surveyed by FactSet had estimated losses of 29 cents a share on revenue of $17.4 million. For the fourth quarter, analysts model losses of 32 cents a share on sales of $21.2 million. Guardant said it expects full-year 2018 revenue of $82 million to $84 million; the FactSet consensus is for revenue of $74.4 million. Guardant stock closed down roughly 10% in Monday trading, with the S&P 500 index falling 1.7%.
Revenue growth of 95% over prior year period REDWOOD CITY, Calif., Nov. 19, 2018 -- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company focused on helping.
SoftBank's Vision Fund portfolio includes a little of everything, from startups that send satellites to space, to one that helps humans walk dogs. Here's what it means for the market.
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
MSI-High Status Now Part of Guardant360® Assay REDWOOD CITY, Calif. , and MUNICH , Oct. 19, 2018 /PRNewswire/ -- New data demonstrating the high sensitivity and specificity of the blood-based Guardant360® ...
REDWOOD CITY, Calif., Oct. 16, 2018 /PRNewswire/ -- A prospective study in patients with advanced non-small cell lung cancer (NSCLC) has demonstrated that the blood based Guardant360® assay, developed by Guardant Health (GH) identified clinically actionable mutations in nearly twice as many patients as tissue biopsy alone. Researchers from the Abramson Cancer Center of the University of Pennsylvania published the findings of the 323-patient study in JAMA Oncology, concluding that the results support routine use of a liquid biopsy blood test to guide treatment of patients with advanced NSCLC.
Only eight of the Bay Area's unicorns have gone public this year. Meanwhile, 24 new ones have been born. Here's a look at all of them.
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Shares of Guardant Health made a staggering debut in the market on Thursday. The cancer detecting company closed up nearly 70% as it debuted on the NASDAQ. Shares of Vaxart Inc. also saw huge gains on news that its oral flu vaccine performed better than Sanofi's Fluzone in a phase 2 trial.